We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The ACCOST-HH Trial.
- Authors
Skurk, Carsten; Rottbauer, Wolfgang; Kessler, Mirjam; Akin, Ibrahim; Kluge, Stefan; Burdelski, Christoph; Blankenberg, Stefan; Zeller, Tanja; Landmesser, Ulf; Karakas, Mahir
- Abstract
The article discusses the AdreCizumab against plaCebO in SubjecTs witH cardiogenic sHock (ACCOST-HH) clinical trial being conducted by cardiologists and intensive care specialists in Germany. Topics explored include the investigation into the efficacy and safety of the monoclonal antibody Adrecizumab, the way Adrecizumab targets bioactive adrenomedullin, and the assessment of tolerability and potential adverse events following treatment.
- Subjects
THERAPEUTIC use of monoclonal antibodies; CARDIOGENIC shock; CLINICAL trials; DRUG efficacy; MEDICATION safety; ADRENOMEDULLIN; DRUG side effects; PHARMACEUTICAL research
- Publication
European Heart Journal, 2020, Vol 41, Issue 45, p4296
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehaa757